Etazocine
Chemical compound
- None
- In general: non-regulated
- 1,2,3,4,5,6-hexahydro-6,11-diethyl-3-methyl-2,6-methano-3-benzazocin-8-ol
or
5,7-diethyl-2-hydroxy-2-methyl-6,7-benzomorphan
- 0135188AB
Y
10286-45-0 ((−)-form (HCl))
- 187767
- 163214
- 25Z262VU9E
- Interactive image
- Oc1ccc3c(c1)[C@@]2([C@H]([C@@H](N(CC2)C)C3)CC)CC
InChI
- InChI=1S/C17H25NO/c1-4-14-16-10-12-6-7-13(19)11-15(12)17(14,5-2)8-9-18(16)3/h6-7,11,14,16,19H,4-5,8-10H2,1-3H3/t14-,16-,17-/m0/s1
- Key:JYRBQCWXZNDERM-XIRDDKMYSA-N
Etazocine (NIH-7856) is an opioid analgesic of the benzomorphan family which was never marketed.[1][2] It acts as a partial agonist of the opioid receptors, with mixed agonist and antagonist effects.[1] In animal studies, it was shown to induce analgesia, dependency, and respiratory depression, with overall effects similar to those of morphine, but with substantially reduced potency in comparison.[1][2][3]
See also
References
- ^ a b c National Research Council (U.S.). Committee on Problems of Drug Dependence, American Medical Association. Committee on Alcoholism and Drug Dependence, American Medical Association. Council on Mental Health, National Academy of Sciences (U.S.) (1969). Bulletin, problems of drug dependence. National Academies. pp. 5820–5821. NAP:10503. Retrieved 22 April 2012.
- ^ a b Smethurst PW, Forrest WH, Hayden J (December 1971). "The respiratory effects of a potent analgesic (GPA 2087) in man". British Journal of Anaesthesia. 43 (12): 1129–35. doi:10.1093/bja/43.12.1129. PMID 5156297.
- ^ National Research Council (U.S.). Committee on Problems of Drug Dependence (1970). Report of the annual scientific meeting. National Research Council. Retrieved 22 April 2012.
- v
- t
- e
modulators
| Calcium blockers |
|
|---|---|
| Sodium blockers |
|
| Potassium openers |
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
